Northwestern University researchers have reengineered a standard chemotherapy drug into a nanostructured form, killing cancer cells up to 20,000 times more effectively while sparing healthy tissues.
This innovative therapy converts the traditional drug into a spherical nucleic acid (SNA), enhancing its solubility and cellular uptake efficiency.
The novel drug was tested on acute myeloid leukemia (AML) in animal models, showing remarkably improved potency and a dramatic reduction in cancer progression with no detectable side effects, marking a significant advancement in cancer treatment.
How Does the New Nanostructured Drug Work?
The research team created the drug from scratch as a spherical nucleic acid (SNA), in which the chemotherapy compound 5-fluorouracil (5-Fu) is chemically incorporated into DNA strands that form a dense shell around a nanoparticle core.
This allows the drug to enter cancer cells more effectively by leveraging the cells' natural scavenger receptors.
Once inside leukemia cells, enzymes break down the DNA shell, releasing the drug directly and significantly increasing its potency while avoiding damage to healthy cells, which are usually harmed in conventional chemotherapy.
Did you know?
Nanostructured drug delivery systems (NDDS) are designed to target cancer cells more specifically, resulting in a lower concentration of the toxic chemotherapy drug in healthy tissues and thus reducing severe side effects like hair loss, nausea, and organ damage.
What Are the Key Results from Animal Studies?
In mouse models of acute myeloid leukemia, the SNA drug entered cancer cells 12.5 times more efficiently compared to the standard form. It killed cancer cells up to 20,000 times more effectively, slowing cancer progression by 59 times, with no notable toxic side effects.
The therapy nearly eliminated leukemia cells in blood and spleen samples and significantly extended survival rates in treated animals, indicating outstanding therapeutic potential.
How Is This Drug Different From Traditional Chemotherapy?
Traditional chemotherapy drugs like 5-Fu often suffer from poor solubility and non-selective attack on both cancerous and healthy cells, leading to severe side effects, including nausea, fatigue, and rare but serious outcomes like heart failure.
The nanostructured drug overcomes these limitations by improving water solubility and targeting, focusing cytotoxic effects specifically on cancer cells and sparing normal tissues, which could transform patient treatment experiences.
ALSO READ | How Did Scientists Film Ribosome Assembly in Real Time?
What Is Structural Nanomedicine?
Structural nanomedicine is an emerging field where the physical and compositional structures of nanomedicines are precisely designed to enhance their behavior and targeting capabilities within the body. This approach fine-tunes drug delivery, efficacy, and safety.
With seven SNA-based therapies already in clinical trials, this technology shows promise not only for cancer but also for infectious diseases, neurodegenerative disorders, and autoimmune conditions, potentially revolutionizing various therapeutic areas.
What Are the Next Steps for This Research?
The research team plans to advance their promising findings through larger animal models, followed by human clinical trials pending funding and regulatory approvals.
The hope is to validate the efficacy and safety in patients and eventually offer a more effective and less toxic chemotherapy alternative.
If successfully translated to clinical practice, this innovation could improve chemotherapy outcomes, reduce side effects, and enhance the quality of life for cancer patients worldwide.
This nanomedicine breakthrough, spearheaded by Chad A. Mirkin, a pioneer in chemistry and nanotechnology at Northwestern University, represents a significant milestone in cancer research.
Comments (0)
Please sign in to leave a comment